| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 646,079 | 593,638 | ||
| Restricted cash | 0 | 0 | ||
| Accounts receivable, net of allowance of 13,313 at september30, 2025 and 11,275 at december31, 2024 | 211,579 | 220,195 | ||
| Inventories | 167,538 | 165,350 | ||
| Prepaid and refundable taxes | 27,531 | 32,785 | ||
| Prepaid expenses and other current assets | 44,422 | 54,174 | ||
| Total current assets | 1,097,149 | 1,066,142 | ||
| Property, plant, and equipment, net | 218,510 | 195,418 | ||
| Goodwill | 791,034 | 793,365 | ||
| Intangible assets, net | 234,530 | 239,143 | ||
| Operating lease assets | 51,197 | 50,677 | ||
| Investments | 15,049 | 16,163 | ||
| Deferred tax assets | 107,305 | 109,810 | ||
| Long-term derivative assets | 28,011 | 21,658 | ||
| Other assets | 14,798 | 14,326 | ||
| Total assets | 2,557,583 | 2,506,702 | ||
| Current debt obligations | 85,440 | 82,133 | ||
| Accounts payable | 88,156 | 86,934 | ||
| Legal and professional costs | 18,481 | - | ||
| Italian medtech payback measure | 12,255 | - | ||
| Contract liabilities | 11,084 | - | ||
| Operating lease liabilities | 9,001 | - | ||
| Provisions for agents, returns, and other | 4,948 | - | ||
| Royalty accrual | 4,660 | - | ||
| Interest payable | 3,235 | - | ||
| Current derivative liabilities | 1,888 | - | ||
| Research and development costs | 1,353 | - | ||
| Restructuring liabilities | 0 | - | ||
| Other accrued expenses | 25,324 | - | ||
| Accrued liabilities and other | 92,229 | 103,240 | ||
| Snia environmental liability | 394,587 | 392,268 | ||
| Current contingent consideration | 49,041 | 48,265 | ||
| Current litigation provision liability | 16,499 | 12,171 | ||
| Taxes payable | 21,373 | 34,495 | ||
| Accrued employee compensation and related benefits | 80,263 | 67,594 | ||
| Total current liabilities | 827,588 | 827,100 | ||
| Long-term debt obligations | 349,031 | 348,489 | ||
| Long-term contingent consideration | 40,641 | 39,662 | ||
| Deferred tax liabilities | 10,096 | 11,392 | ||
| Long-term operating lease liabilities | 43,075 | 42,777 | ||
| Long-term employee compensation and related benefits | 13,543 | 13,651 | ||
| Long-term derivative liabilities | 64,515 | 48,093 | ||
| Other long-term liabilities | 51,864 | 52,699 | ||
| Total liabilities | 1,400,353 | 1,383,863 | ||
| Ordinary shares, 1.00 par value unlimited shares authorized 55,503,264 shares issued and 54,605,279 shares outstanding at september30, 2025 54,437,670 shares issued and 54,348,542 shares outstanding at december31, 2024 | 84,520 | 84,521 | ||
| Additional paid-in capital | 2,245,024 | 2,234,777 | ||
| Accumulated other comprehensive income (loss) | 5,508 | 8,113 | ||
| Accumulated deficit | -1,176,627 | -1,203,411 | ||
| Treasury stock at cost, 897,985 ordinary shares at september30, 2025 89,128 ordinary shares at december31, 2024 | 1,195 | 1,161 | ||
| Total stockholders equity | 1,157,230 | 1,122,839 | ||
| Total liabilities and stockholders equity | 2,557,583 | 2,506,702 | ||
LivaNova PLC (LIVN)
LivaNova PLC (LIVN)